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INTRODUCTION
Most  strokes  are  ischemic  in  origin;  of  these 
80% are caused by arterial occlusion secondary to 
atherosclerosis (B a m f o r d et al., 1990). Evidence 
indicates that modifiable risk factors (such as lipids 
and  lipoproteins)  interact  with  genetic  factors  to 
cause stroke (E l b a z  et al., 1999). Studies in twins, 
families, and animal models provide substantial evi-
dence for a genetic contribution to ischemic stroke 
(Jeffs et al., 1997; S c h u l z et al., 2004). The genet-
ic factors seem to be more important in large-vessel 
stroke and small vessel stroke than in cryptogenic 
stroke, and there is no epidemiological evidence for 
a genetic component in cardioembolic stroke (S c h 
u l z  et al., 2004; J e r r a r d-D u n n e  et al., 2003). 
This finding emphasizes the importance of stroke 
subtypes and lends support to the view that large-
vessel stroke and myocardial infarction share similar 
pathological mechanisms and genetic susceptibility 
(D i c h g a n s, 2007).
Apolipoprotein  B  (apoB)  plays  a  central  role 
in  lipoprotein  metabolism.  It  is  a  component  of 
chylomicrons, low-density lipoproteins (LDL), very 
low-density lipoproteins (VLDL), and intermediate-
density lipoproteins (IDL), as well as the ligand for 
the LDL receptor (M a h l e y et al., 1984). The given 
lipoprotein has numerous polymorphic sites. Among 
them are polymorphisms assigned according to the 
presence/absence of the cutting site of the restriction 
enzymes XbaI, EcoRI, and MspI; the 4311 Asn→Ser 
substitution; and an insertion/deletion of nine base 
pairs (I/D) in the signal peptide (Rengees  et al., 
1992). ApoB gene polymorphisms XbaI, EcoRI, and 
MspI  has  been  previously  linked  with  variability 
of serum lipid levels and the risk of coronary ath-
erosclerosis in several populations (Humphries,  
1988; K a m e r e e r et al., 1996; Hansen  et al., 
1994; D e l g h a n d i et al.; 1999, S t e p a n o v et 
al.,  1998). I/D polymorphism has also been linked 
with variations in plasma cholesterol and CAD risk 
(H u m p h r i e s,  1988; Kamereer  et al., 1996; 
Peacock et al., 1992, P e a c o c k et al., 1994). The 
X-, R-, and I alleles of the above-mentioned loci have 
been reported as risk factors for CAD (B o h n et 
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al.,1993; H u m p h r i e s,  1988; H e g e l e and B r e- 
s l o w, 1987; P e a c o c k et al.,  1992, P e a c o c k et 
al., 1994). It was also suggested that apoB gene poly-
morphisms may modulate plasma lipid/lipoprotein 
and glucose levels in patients with type 2 diabetes 
(D u m a n et al., 2006). The apoB gene has so far 
been mainly investigated in familiar hypercholester-
olemia and coronary artery diseases. Accordingly, 
the aim of our study was to investigate the possible 
association of five polymorphisms in the apoB gene 
(XbaI,  EcoRI,  MspI,  Ins/Del,  and  4311A/G)  with 
ischemic cerebrovascular disease in Serbia.
MATERIAL AND METHODS
Sample
Blood samples were obtained from 60 patients 
who had suffered a completed stroke or a transient 
ischemic  attack.  These  were  proven  by  computer 
tomography  or  magnetic  resonance  of  the  brain. 
Atherosclerosis of the eye bottom as well as both 
carotids and vertebral arteries was assessed by ultra-
sound  examination.  The  control  group  consisted 
of  245  unrelated  healthy  Serbian  subjects  whose 
annual  health  examination  showed  them  to  be 
free  of  cerebrovascular,  cardiovascular,  or  chronic 
inflammatory disease. The control group was body 
mass index matched (BMI) with patients. Informed 
consent was obtained from each participant in the 
study. Personal data (age, sex, weight, height, and 
blood pressure) were obtained from all participants. 
All subjects with a personal or family history of dia-
betes and/or thyroid dysfunction were excluded, as 
well as individuals taking any lipid-lowering drugs. 
Blood samples were collected from participants 
after 12 hours of fasting. The total plasma cholesterol 
(TC) and triglyceride (TG) levels were determined 
on  a  Monarch  Plus  apparatus  (Instrumentation 
Laboratory, Lexington, USA) using enzymatic colo-
rimetric  methods.  The  HDL  cholesterol  (HDLC) 
was determined after dextran sulfate – Mg2+ pre-
cipitation of VLDL and LDL, using the CHOD-PAP 
method. The LDL cholesterol (LDLC) was calculated 
using the Friedewald formula (F r i e d e w a l d et al., 
1972) for participants with triglyceride levels <4.5 
mmol/l. All reagent kits were from Instrumentation 
Laboratory  (Lexington,  USA).  Serum  apoA-I  and 
serum  apoB  were  quantified  by  immunonephe-
lometry with reagents from Beckman Instruments 
(Fullerton, CA).
DNA analysis 
Genomic DNA was isolated from whole blood 
cells by proteinase K digestion and phenol/chloro-
form extraction (K u n k e l et al., 1977). Genomic 
fragments  containing  apoB  gene  polymorphisms 
XbaI (codon 2488, exon 26), EcoRI (codon 4154, 
exon 29), MspI (codon 3611), point mutation A/G at 
nucleotide 12932 (codon 4311, exon 29), and Ins/Del 
(signal peptide) were amplified by the polymerase 
chain reaction (PCR) on a Touch DownTM thermal 
cycler (Hybaid, Teddington, UK). Genotypes were 
determined by RFLP and/or gel electrophoresis as 
previously described (G l i š i ć et al., 1995; Glišić 
et al., 1997; G l i š i ć and A l a v a n t i ć, 1996; 
Rajput-W i l l i a m s et al., 1988) and visualized 
by the GDS8000 gel documentation system (Ultra 
Violet Products Inc., Upland, CA). 
Statistical analysis
Conformance of the allele frequencies to Hardy-
Weinberg  equilibrium  proportions  was  tested  by 
the χ2 test. Genotype and allele frequencies in dif-
ferent groups were compared by the gene counting 
method and chi-squared analysis. The unadjusted 
odds ratios and their 95% confidence intervals (CI) 
were also calculated. The Student t-test was used to 
compare differences between two means. If the dis-
tribution of quantitative variables was skewed, log-
transformed values were used for the analysis. In all 
tests, differences with two-tailed alpha–probability 
(P)  ≤0.05  were  considered  statistically  significant. 
The correction for multiple testing was performed 
by multiplying the p value by the number of poly-
morphisms analyzed in the study. For the analysis, 
we used the Statistica software package (Version 5, 
Stat Soft Inc., 1997). 
RESULTS
Description of the population
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lipid and lipoprotein variables are presented in Table 
1. The patient group was generally older and had 
significantly lower HDL, but also higher triglyceride 
and apoB levels. Blood pressure values were signifi-
cantly higher in the patients than in the controls. 
Genotypes and susceptibility to ICVD
The  genotype  and  allele  frequencies  of  apoB 
gene  polymorphisms  XbaI,  EcoRI,  MspI,  Ins/Del, 
and 4311 A/G in the patients with ICVD and con-
trols are shown in Table 2. The observed genotype 
frequencies did not significantly differ from expect-
ed values according to the Hardy-Weinberg equilib-
rium, except for the Ins/Del polymorphism ones in 
the controls (G l i š i ć et al., 1997). The frequency 
of the apoB X+ allele was significantly higher in the 
ICVD patients than in the controls (P<0.05). The 
odds ratio (OR) for ICVD in the X+X+ genotype 
was 2.22, 95% CI 1.24-3.96. Frequency of the apoB 
Ins allele was also significantly higher in the ICVD 
patients compared to the controls (P<0.05). The OR 
for ICVD in the Ins/Ins genotype was 2.82, 95% CI   
1.57-5.06. The patients with ICVD had significantly 
higher frequency of the apoB 4311A allele compared 
to the controls (P<0.01). We did not calculate the OR 
for carriership of the A allele, since all investigated 
patients had carrier status. No significant differences 
of  genotype  and  allele  frequency  distribution  for 
either the EcoRI or the MspI polymorphism at the 
apoB gene were observed between the patients and 
the controls. 
DISCUSSION
The plasma concentration of apoB has recently 
been  reported  to  be  the  best  lipid  predictor  of 
coronary  heart  disease  (S  n  i  d  e  r  m  a  n    and 
Marcovina, 2006; P i s c h o n et al., 2005). There 
is growing evidence indicating that a number of risk 
factors are shared between coronary heart disease 
and  cerebrovascular  disease  (P  e  a  r  s  o  n  et  al., 
2002). Although cerebrovascular insufficiency may 
be caused by a variety of pathophysiological mecha-
nisms, it is known that many possible risk factors 
(such as disturbance of lipid profile and sequence 
variations in genes coding for apolipoproteins) can 
accelerate  the  development  of  atherosclerosis  and 
result  in  stroke.  Information  about  the  effects  of 
apoB  gene  polymorphisms  in  ICVD  still  remains 
scanty.  Previously,  Ins/Del  polymorphism  of  the 
apoB gene has been linked with CAD risk (Hansen 
et al., 1994). Our results are compatible with those 
linking the Ins allele or the Ins/Ins genotype with 
CAD  or  with  severity  of  coronary  atherosclerosis 
at the first angiography (R e g i s-B a i l e y et al., 
Parameter ICVD Patients Controls P value*
n 60 245
Age (years) 50.73 ± 13.09 40.48 ± 15.01 <0.05
Smokers-n (%)* 38 (63.3) 154 (62.9) NS
Body mass index (kg/m2) 25.42 ± 2.74 26.32 ± 3.69 NS
Total cholesterol (mmol/l)  6.07 ±1.51  5.75 ± 0.68 NS
HDL-cholesterol (mmol/l) 1.20 ± 0.49 1.55 ± 0.39 <0.05
LDL-cholesterol (mmol/l) 3.65 ± 1.48 3.72 ± 1.06 NS
Triglycerides (mmol/l)# 2.05± 0.86 1.38 ± 0.80 <0.05
Systolic blood pressure (mm Hg)# 161.10±29.52  129.55±22.16  <0.05
Diastolic blood pressure (mm Hg)# 97.13±14.41  82.26±12.06  <0.05
apoA (g/L) 1.36±0.33  1.31±0.38  NS
apoB (g/L) 1.46±0.53  0.97±0.36  <0.05
Values are expressed as means ± SD; # analyses were performed with log transformed values; P value from t-test; *χ2 –test; NS non-
significant.
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1996; P e a c o c k et al., 1992). In the present study, 
individuals carrying the Ins/Ins genotype presented 
2.82-fold increased risk for development of ICVD. 
Although our study was limited in the number of 
ICVD patients, this risk remained significant even 
after  correction  for  multiple  testing.  It  was  also 
recently reported that the Ins/Ins genotype confers 
a 2.2 times higher risk for an unfavorable course of 
ischemic heart disease in the population of Russia 
(Zateishchikov et al., 2004).
XbaI polymorphism of the apoB gene has also 
been  linked  with  atherosclerosis  in  a  number  of 
studies from different populations. Even frequency 
of the rare X+ allele was significantly lower in the 
Chinese  Han  population  than  that  reported  in 
apoB Genotypes ICVD patients Controls P 
and alleles n=60 % n =245 % ( χ2)
XbaI X+X+ 37 61.67 103 42.04
X+X- 20 33.33 124 50.61 <0.05
X-X- 3 5.00 18 7.35
Allele X+ 94 78.33 330 67
<0.05
X- 26 21.67 160 33
EcoRI R+R+ 31 51.67 146 68.60
R+R- 26 43.33 91 29.70 NS
R-R- 3 5.00 8 1.70
Allele R+ 88 73.33 383 78.16
R- 32 26.67 107 21.84 NS
MspI M+M+ 23 38.33 118 48.16
M+M- 34 56.67 115 46.94 NS
M-M- 3 5.00 12 4.90
Allele M+ 80 66.67 351 71.63
M- 40 33.33 139 28.37 NS
Ins/Del InsIns 29 48.33 61 24.90
InsDel 21 35.00 155 63.26 <0.001
DelDel 10 16.67 29 11.84
Allele Ins 79 65.83 276 56.32
<0.05
Del 41 34.16 214 43.67
4311 AA 31 51.66 97 39.59
AG 29 48.33 115 46.94 <0.05
GG 0 0 33 13.47
Allele A 91 75.83 309 63.06
<0.01 G 29 24.17 181 36.94
Table 2. Genotype and allele frequencies of apolipoprotein B-100 gene polymorphisms XbaI, EcoRI, MspI, Ins/Del, and  4311 A/G 
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Caucasians (0.027 vs. 0.418) (X- was the most fre-
quent one in this population), and higher frequency 
of the X+ allele was found in the Chinese Han ath-
erosclerotic cerebral infarction group compared to 
controls (0.053 vs. 0.027, P < 0.05) (W a n g et al., 
1999). Alto-Setala and co-workers discerned no sta-
tistically significant association between XbaI alleles 
and cerebrovascular atherosclerosis (A l t o-S e t a l a 
et al., 1998), while two other studies showed a higher 
prevalence of the X+X+ genotype or X+ allele in 
patients with arterial disease (M a n s u r et al., 2000; 
M o n s a l v e et al., 1988), which is in agreement 
with  our  results.  Individuals  carrying  the  X+X+ 
genotype had a 2.22-fold increased risk of develop-
ing ICVD. This association was no longer significant 
after correction for multiple testing.
The point mutation (A/G) at codon 4311 of the 
apoB gene was less thoroughly examined in recent 
reports. In the control group, frequency of the allele 
G (0.37) is among the highest in Caucasian popula-
tions. Rare homozygotes (GG) were not present in 
the Serbian ICVD group. A similar trend of lower 
GG frequency was observed in patients with myo-
cardial infarction compared to controls (M o r e e l et 
al., 1992). The 4311 polymorphism had a significant 
effect on high density lipoprotein (HDL) cholesterol 
levels in a study of young myocardial infarction sur-
vivors  and  healthy  population-based  individuals 
(Peacock et al., 1992). In our study, patients with 
ICVD had a significantly higher frequency of the A 
allele, which remained significant after correction 
for multiple testing. 
We  did  not  observe  significant  differences  of 
genotype distribution and relative allele frequencies 
for the EcoRI and MspI polymorphisms in the apoB 
gene. These data are in accordance with some of pre-
vious reports (D e l g h a n d i et al., 1999; Salazar 
et al., 2000). Others found the common M+ allele 
of the MspI RFLP polymorphism more frequently 
present in CAD patients than in controls, but no 
significant  differences  of  allele  frequencies  were 
observed  for  the  XbaI  and  EcoRI  polymorphisms 
(Stepanov et al., 1998).
It is very important that the control group in the 
present study was matched with patients according 
to  BMI  values,  since  recent  findings  showed  that 
increased BMI is a risk factor for both total and isch-
emic stroke (H u et al., 2007). In addition to the dif-
ferent design of the previous studies, inconsistencies 
of the results might be attributable to different apoB 
haplotype distributions in the different populations 
studied. Also, most previous studies were focused on 
the effect of apoB gene polymorphisms on changes 
in lipid levels. There is a possibility that some of the 
polymorphisms may act through mechanisms not 
directly related to influence on measured lipid traits. 
Also, the significant effect of certain polymorphisms 
that we found could be due to linkage disequilib-
rium with other functional genetic markers.
There are no previous data on genotype distri-
bution, allele frequencies or correlation of the apoB 
Ins/Del, EcoRI, MspI, XbaI, and 4311 A/G polymor-
phisms with ICVD in Serbian patients. Our study 
suggests association between polymorphisms in the 
apoB gene and ICVD in subjects of Serbian origin 
and supports the assumption that apoB polymor-
phisms may contribute to the extent of cerebrovas-
cular risk. Insight into the genetic profile of affected 
subjects before the onset of ICVD clinical symptoms 
could  have  immediate  clinical  and  public  health 
benefits in predicting ICVD risk. Future studies on 
larger  and  independent  samples  and  in  different 
populations could confirm our results and elucidate 
these relations with a higher power of clarification.
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ПОЛИМОРФИЗМИ ДНК У ГЕНУ ЗА АПОЛИПОПРОТЕИН Б КОД ПАЦИЈЕНАТА СА 
ИСХЕМИЈСКОМ БОЛЕШЋУ МОЗГА ИЗ СРБИЈЕ
АЛЕКСАНДРА СТАНКОВИЋ1, САЊА СТАНКОВИЋ2, ЗАГОРКА ЈОВАНОВИЋ-МАРКОВИЋ3,
МАЈА ЖИВКОВИЋ1, ТАМАРА ђУРИЋ1, САЊА ГЛИШИЋ-МИЛОСАВЉЕВИЋ1, и Д. АЛАВАНТИЋ1
1Инситут за нуклеарне науке “Винча”, 11000 Београд, Србија 
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3Институт за неурологију, Клинички центар Србије, 11000 Београд, Србија 
Конﾭценﾭтрација  аполипопротеинﾭа  Б  (apo  B) 
у хуманﾭој плазми представља нﾭајбољи липиднﾭи 
предикﾭтор кﾭоронﾭарнﾭих болести. Генﾭ за аполипо-
протеинﾭ    садржи  великﾭи  број  полиморфизама 
ДНК,  кﾭојису  до  сада  испитиванﾭи  углавнﾭом  у 
асоцијацији  са  нﾭивоима  липида  и  кﾭоронﾭарнﾭим 
болестима.  Циљ  студије  је  био  да  се  испита 
потенﾭцијалнﾭа асоцијација полиморфизама ДНК 
у генﾭу за apoB (XbaI, EcoRI, MspI, Ins/Del, 4311 
A/G  полиморфизми)  са  исхемијскﾭом  болешћу 
мозга  (IBM)  у  хуманﾭој  популацији  из  Србије. 
Узоракﾭ пацијенﾭата и кﾭонﾭтрола су одабиранﾭи по 
екﾭвиваленﾭтнﾭим  вреднﾭостима  инﾭдекﾭса  телеснﾭе 
масе. Однﾭос шанﾭси за подложнﾭост IBM кﾭод нﾭоси-
оца генﾭотипа X+X+ је био 2.22, 95% CI 1.24-3.96 
(P<0.05), а кﾭод нﾭосиоца генﾭотипа Ins/Ins 2.82, 95% 
CI 1.57-5.06 (P<0.05). Такﾭође, пацијенﾭти су имали 
знﾭачајнﾭо већу фрекﾭвенﾭцију алела 4311А у однﾭо-
су нﾭа кﾭонﾭтроле (P<0.01). Резултати ове студије 
укﾭазују нﾭа знﾭачајанﾭ утицај полиморфизама ДНК 
у генﾭу за apo B нﾭа повећање ризикﾭа за нﾭастанﾭакﾭ 
исхемијскﾭе болести мозга. 